About Us

Timothy Wiegand, MD, FACMT, FAACT, DFASAM


Biography and Statement

Timothy Wiegand, MD, FACMT, FAACT, DFASAM

1. How would your election benefit ASAM and the field of addiction medicine?

I want to continue my work in education and to create awareness between toxicology and addiction medicine and find ways to have collaboration between ACMT and ASAM and its members (many individuals are dual members). I would like to see collaboration with ACMT and medical toxicology and ASAM and Addiction Medicine much like Addiction Psychiatry and Addiction Medicine with overlap and opportunities to leverage experience and expertise.

Additionally, I want to serve in advocacy and create awareness of addiction medicine as a practice pathway for medical toxicology physicians, and others, and to use my expertise to develop new and accessible means of educating and mentoring physicians and trainees in addiction medicine. When different specialties collaborate critically important areas of addiction medicine are often better supported. Emergency Department and hospital care of individuals with opioid use disorder and other addictive disorders is critically important given the importance that hospitals and EDs have within the public health infrastructure.

Unfortunately, this is an area that is often ill-equipped to support patients with addictions. If elected I will work to foster collaborations between specialties and create awareness of resources that can be used to support EDs and hospitals and then move to develop protocols and support for this type of activity. working on advocacy efforts and parity will be critical to these activities as well. I want to also serve in education and conference activities in order to continue to provide ASAMs high quality offerings to its members.

2. What are your greatest contributions to ASAM and the field of addiction medicine?

My own professional work includes patient care and other activities that are at the intersection of addiction medicine and medical toxicology. I see addiction medicine practice activities and professional certification are opportunities that are available to others in my primary specialty, medical toxicology. As toxicologists have unique skill sets enhancing this with addiction medicine training as a specific professional pathway for medical toxicologists adds value for physicians that pursue this and highlights opportunity to collaborate between two specialty groups (e.g. ASAM and ACMT).

I was the founding member of the ACMT Addiction Medicine Committee and have developed curriculum for national meetings and other activities so that in just 5 years nearly 8 % of our currently board-certified medical toxicologists have fulfilled practice pathway criteria and become boarded in addiction medicine as well. ASAM has a medical toxicology work group/committee and there have been numerous cross disciplinary presentations at a variety of events.

To create awareness and educate and advocate for this content and professional pathway as part of medical toxicology I have developed content for our meetings (including chairing a satellite conference "ACMT Addiction Academy" and coordinated several medical toxicology presentations at the annual ASAM conference. I have also presented extensively on withdrawal and intoxication management and on the use and interpretation of urine buprenorphine metabolite levels. I am involved in ongoing mentorship and education activities supporting residents, fellows, early career physicians and many others in a variety of capacities including as mentor, through ECHO education (as facilitator in Rochester NY for a "pain and addiction" ECHO) and in other areas. I helped found and currently serve as Associate Program Director for the UR Medicine Combined Addiction Medicine Fellowship Program.

Biographical Sketch

Timothy J. Wiegand, MD, FACMT, FAACT, FASAM specializes in Medical Toxicology and Addiction Medicine. He is an Associate Professor of Emergency Medicine and the Director of Toxicology at Strong Memorial Hospital and for UR Medicine. Dr. Wiegand is also the Medical Director of Huther Doyle, an addiction services provider in Rochester, New York, where he works in a collaborative model providing a variety of services for patients with substance use disorders and serves as facilitator for their Project ECHO program on pain, opioid prescribing and addiction. In addition to ED, hospital and clinic work treating drug exposure, intoxication and withdrawal Dr. Wiegand is involved with medical education and research in toxicology and addiction. He is the Associate Program Director for the UR Medicine Combined Addiction Medicine Fellowship, which graduated their first Fellowship-trained Addiction Medicine physician this past July and he is core faculty for the Emergency Medicine residency at Strong Memorial Hospital. He lectures locally, regionally and nationally on topics in addiction medicine and medical toxicology and serves on the Board of Directors for several state and national organizations including the American College of Medical Toxicology, the Medical Toxicology Foundation and of the New York Society of Addiction Medicine. Dr. Wiegand is particularly interested in education in addiction medicine and the integration and collaboration between addiction medicine and medical toxicology. To this end he has served on the Addiction Medicine Committee for the American College of Medical Toxicology and coordinated several presentations from toxicologists at the annual scientific meeting for ASAM as well as for his state chapter, NYSAM. He has been awarded the Millennium Labs Late Breaking Abstract Research Award twice with submissions on A.) Addiction medicine training in medical toxicology fellowship programs and B.) the interpretation of buprenorphine metabolite levels in urine drug testing.